Nan Fung Group Holdings Ltd Reduces Stock Holdings in DBV Technologies S.A. (NASDAQ:DBVT)

Posted by James Quigley on Apr 19th, 2025

Nan Fung Group Holdings Ltd cut its holdings in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 80.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,095 shares of the company’s stock after selling 148,380 shares during the quarter. Nan Fung Group Holdings Ltd owned about 0.18% of DBV Technologies worth $115,000 at the end of the most recent reporting period.

DBV Technologies Stock Up 0.9 %

Shares of DBVT stock opened at $7.98 on Friday. DBV Technologies S.A. has a 52-week low of $2.20 and a 52-week high of $8.50. The stock has a market cap of $164.16 million, a PE ratio of -1.77 and a beta of -0.08. The business has a 50-day simple moving average of $5.45 and a 200-day simple moving average of $4.28.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The company had revenue of $0.51 million during the quarter. Sell-side analysts anticipate that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DBVT shares. StockNews.com assumed coverage on DBV Technologies in a research note on Tuesday. They set a “hold” rating on the stock. JMP Securities reiterated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

Check Out Our Latest Stock Report on DBVT

DBV Technologies Profile

(Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.